Clinical trial
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of…
NCT00429260 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00429260 |
|---|---|
| Title | A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression |
| Official title | A 1-week, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug |
| Interventions | Saredutant |
| Enrollment | 125 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jan 31, 2007 |
| Last update posted | Feb 17, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: